What question did this study set out to answer?

This research aims to identify differential tumor microenvironment responses to neoadjuvant chemotherapy with and without pembrolizumab in early triple-negative breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PD7-02: Transcriptomic profiling of the tumor microenvironment indicates differential response to neoadjuvant chemotherapy with and without pembrolizumab in early TNBC

View Full Paper

Ask AI

Bookmark

Authors

JZJ. Gomez Tejeda ZanudoDana-Farber Cancer Institute SKSophie A. KirschnerAstraZeneca (United Kingdom)APA. PatelDana-Farber Cancer Institute

Discussion

Member takes

Implication

A multicenter study reveals that the tumor microenvironment influences response to neoadjuvant chemotherapy in early TNBC, indicating potential biomarkers for treatment efficacy.

Key Points

This research aims to identify differential tumor microenvironment responses to neoadjuvant chemotherapy with and without pembrolizumab in early triple-negative breast cancer.
Prospective analysis of TNBC patients using baseline and post-treatment tissue samples.
Quantification of RNA expression via whole transcriptome sequencing.
Assessment of tumor microenvironment cell type abundance through TIMER3 deconvolution methods.
Statistical comparisons using linear models and Cox proportional hazards models for survival analysis.
Twenty percent of patients receiving neoadjuvant CT-P achieved pathologic complete response (pCR).
Higher baseline abundance of proinflammatory cell types is associated with pCR in patients receiving CT-P.
Increased dendritic cells correlate with a higher likelihood of pCR with CT-P compared to CT alone.
Post-treatment revealed a unique tumor microenvironment signature, with lower suppressive tumor-associated macrophages (TAMs) following CT-P.
Higher total TAMs post-treatment are linked to improved overall survival in the CT-P group.

Cite This Study

Zanudo et al. (2026) studied this question.

synapsesocial.com/papers/6996a85cecb39a600b3eefc8 https://doi.org/10.1158/1557-3265.sabcs25-pd7-02

View Full Paper

Ask AI

Bookmark

Implication

A multicenter study reveals that the tumor microenvironment influences response to neoadjuvant chemotherapy in early TNBC, indicating potential biomarkers for treatment efficacy.

Abstract PD7-02: Transcriptomic profiling of the tumor microenvironment indicates differential response to neoadjuvant chemotherapy with and without pembrolizumab in early TNBC

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PD7-02: Transcriptomic profiling of the tumor microenvironment indicates differential response to neoadjuvant chemotherapy with and without pembrolizumab in early TNBC

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider